Coronary/Structural Heart

RenalGuard Solutions Announces Late Breaking Clinical Trial Data Accepted for Presentation at Heart Failure 2018

MILFORD, Mass.–(BUSINESS WIRE)–RenalGuard Solutions™, Inc., a medical device company focused on innovative fluid management technologies for the cardiac and vascular markets, today announced that new data from a clinical trial studying RenalGuard®-Guided Diuretic Therapy will be presented as a late breaking abstract at Heart Failure 2018, the annual meeting of […]

Independent Stent Imaging Study Shows Excellent Healing Profile with Resolute Onyx DES in Complex Patients with Coronary Artery Disease

DUBLIN and PARIS- May 24, 2018 – Investigators today unveiled clinical data from the independently run Onyx 1-Month OCT Study, which showed strong early vessel healing in a patient population that contained a high percentage of patients with complex coronary artery disease who were implanted with the Resolute Onyx(TM) DES at […]

Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR

DURHAM, N.C., May 23, 2018 /PRNewswire/ — A 24-month update on the DESSOLVE III trial of the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent) was presented this week at EuroPCR 2018, an international congress of interventional cardiovascular medicine researchers and clinicians held in Paris, France. Data were presented by William Wijns, M.D., Ph.D., […]

CeloNova Announces Positive Clinical Results of eCOBRA Study at EuroPCR 2018

SAN ANTONIO, May 23, 2018 /PRNewswire/ — CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today announced 1-year clinical trial results from the eCOBRA post-market study of the company’s COBRA PzF™ NanoCoated Coronary Stent (NCS) System. The clinical trial […]

PiCSO therapy reduces infarct size in STEMI patients.

AWANS, Belgium, May 24, 2018 /PRNewswire/ — Miracor Medical SA announced today the clinical results from the physician-sponsored OxAMI-PiCSO study were published in the EuroIntervention journal and presented at the Hotline session of the EuroPCR conference by Dr. Giovanni Luigi De Maria, MD, the Heart Centre, Oxford University Hospitals, Oxford, UK. The latest results, obtained with the PiCSO® Impulse System, contribute to the […]

QT Vascular Enters Into Asset Purchase And Option Agreement With Teleflex

SINGAPORE, May 24, 2018 /PRNewswire/ — QT Vascular Ltd., (“QT Vascular“, and with its subsidiaries, the “Company“), announced today that it has entered into an asset purchase and option agreement (the “APOA“) with Teleflex Life Sciences Unlimited Company and Teleflex Incorporated (“Teleflex“). Under the APOA, Teleflex will acquire the non-drug coated product line […]

Venus Medtech’s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

HANGZHOU, China, May 23, 2018 /PRNewswire/ — China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation TriGUARD 3™ device and the next generation of cerebral embolic protection device in China and […]

New Medtronic Data Show Significant Blood Pressure Lowering Effect of Renal Denervation in Patients Taking Anti-Hypertensive Medication

DUBLIN and PARIS – May 23, 2018 – Medtronic plc (NYSE:MDT) today announced first-ever-data from the SPYRAL HTN-ON MED Study. Initial study results found statistically significant and clinically important blood pressure reductions in hypertensive patients prescribed anti-hypertension medications treated with the Symplicity Spyral renal denervation (RDN) system with no major adverse […]

Fantom’s Positive Two-Year Results Show Sustained Safety and Efficacy

SAN DIEGO, May 23, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, reported sustained safety and efficacy of the Fantom®bioresorbable scaffold (“BRS”) through two years based on data from the FANTOM II trial presented today at the […]

Berlin Cures Announces Formation of Scientific Advisory Board

ZUG, Switzerland, May 23, 2018 /PRNewswire/ — Drug developer Berlin Cures today announced the formation of a Scientific Advisory Board (SAB) and the appointment of its first two members, Prof. Beda M. Stadler and Prof. Wilhelm Vetter, to help advance the clinical development of BC 007, the first drug designed to target the autoimmune cause of heart failure as […]